BAGALUR CALL GIRL IN 98274*61493 ❤CALL GIRLS IN ESCORT SERVICE❤CALL GIRL
Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends in Egypt, Jordan, Israel, Saudi Arabia and UAE)
1. Get more info on this report!
Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends in
Egypt, Jordan, Israel, Saudi Arabia and UAE)
November 1, 2008
At present the Middle East region constitutes as small percent of global pharmaceutical
sales. However, ever-increasing populations and governmental healthcare reforms are
likely to increase demand. These markets will be essential for pharmaceuticals
companies exploring new opportunities for growth. Developing regions will be an
integral part of expansion for companies looking to capture a larger portion of the
worldwide market.
This Kalorama Information report, Pharmaceutical Markets in the Middle East
(Opportunities, Key Players, Trends) takes a thorough look at the emerging markets in
these countries:
• Egypt
• United Arab Emirates
• Isreal
• Saudi Arabia
• Jordan
As part of its exhuastive coverage, for each country's market, the report includes:
• Current Pharmaceutical Market Size
• Market Forecast
• Regulatory Environment
• Economic Statistics
• Disease and Health Spending Statistics
• Leading Pharmaceutical Suppliers
In addition, trends that apply to all countries such as generic competition, regulatory
matters, Companies profiled in this report include:
2. • Banaja
• Dar Al Dawa
• GlaxoSmithKline Egypt
• Gulf Pharmaceutical Industries
• Hikma Pharmaceuticals
• Medical Union Pharmaceutical Company
• Perrigo Israel
• Pharco Pharmaceuticals
• Saudi Pharmaceutical Industries & Medical Appliances Corp.
• TEVA
The information for this report was gathered using both primary and secondary research
including comprehensive research of secondary sources such as company literature,
databases, investment reports, and medical and business journals. Telephone
interviews and email correspondence were the primary method of gathering information.
For the purpose of this study, Kalorama Information conducted interviews with more
than 30 key industry officials, consultants, health care providers, and government
personnel. These sources were the primary basis in gathering information specifically
relating to revenue and market share data presented in this report. Additional interviews
were completed with relevant company representatives including marketing directors,
division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year
for data was 2007. Historical data was provided for the years 2005 and 2006, with
forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs)
are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment
covered. The forecasted market analysis for 2008-2012 was largely based on
demographic trends, new developments, and global expansion.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
• Overview
• Scope and Methodology
• Size and Growth of the Market
• Key Issues and Trends Affecting the Market
• Leading Competitors
CHAPTER TWO: INTRODUCTION
• Overview
• Intellectual Property Rights and Compulsory Licensing
• Biosimilar Production
3. • World Health
• Tobacco Use
• Obesity
CHAPTER THREE: PHARMACEUTICAL MARKETS IN ISRAEL
• Overview and Summary
• Regulatory Environment
• Intellectual Property Rights
• Economic Development
• GDP and Healthcare Spending
• Healthcare Trends in Israel
• Demographics
o Birth Rates
o Life Expectancy
o Mortality
• Key Product Segments and Market Indicators
o Cardiovascular Disease
o Infection Control Disease
o Central Nervous System Drugs
o Oncology
• Market Analysis
• Sales of Pharmaceuticals by Generic Supply
• Leading Pharmaceutical Suppliers
CHAPTER FOUR: PHARMACEUTICAL MARKETS IN EGYPT
• Overview and Summary
• Regulatory Environment
• Economic Development
• GDP and Healthcare Spending
• Healthcare Trends in Egypt
• Demographics
• Birth Rates
• Life Expectancy
• Mortality
• Key Product Segments and Market Indicators
• Cardiovascular Disease
• Infection Control
• Oncology
• Diabetes
• Market Analysis
• Sales of Pharmaceuticals by Generic Supply
• Leading Pharmaceutical Suppliers
CHAPTER FIVE: PHARMACEUTICAL MARKETS IN SAUDI ARABIA
4. • Overview and Summary
• Regulatory Environment
• Intellectual Property Rights
• Economic Development
• GDP and Healthcare Spending
• Healthcare Trends in Saudi Arabia
• Demographics
• Birth Rates
• Life Expectancy
• Mortality
• Key Product Segments and Market Indicators
• Cardiovascular Disease
• Infection Control
• Oncology
• Diabetes and Other Diseases
• Market Analysis
• Sales of Pharmaceuticals by Generic Supply
• Leading Pharmaceutical Suppliers
CHAPTER SIX: PHARMACEUTICAL MARKETS IN JORDAN
• Overview and Summary
• Regulatory Environment
• Intellectual Property Rights
• Economic Development
• GDP and Healthcare Spending
• Healthcare Trends in Jordan
• Jordanian Insurance Coverage
• Demographics
• Birth Rates
• Life Expectancy
• Mortality
• Key Product Segments and Market Indicators
• Cardiovascular Disease
• Infection Control
• Oncology
• Diabetes
• Market Analysis
• Sales of Pharmaceuticals by Generic Supply
• Leading Pharmaceutical Suppliers
CHAPTER SEVEN: PHARMACEUTICAL MARKETS IN THE UNITED ARAB
EMIRATES
• Overview and Summary
• Regulatory Environment
5. • Intellectual Property Rights
• Economic Development
• GDP and Healthcare Spending
• Healthcare Trends in the UAE
• Demographics
• Birth Rates
• Life Expectancy
• Mortality
• Key Product Segments and Market Indicators
• Cardiovascular Disease
• Infection Control
• Oncology
• Diabetes
• Market Analysis
• Sales of Pharmaceuticals by Generic Supply
• Leading Pharmaceutical Suppliers
CHAPTER SEVEN: MARKET SUMMARY
• Overview
CHAPTER EIGHT: LEADING PHARMACEUTICAL PROVIDERS IN THE MIDDLE
EAST
• Overview
• Banaja
• Dar Al Dawa
• GlaxoSmithKline Egypt
• Gulf Pharmaceutical Industries (Julphar)
• Hikma Pharmaceuticals
• Medical Union Pharmaceutical Company
• Perrigo Israel
• Pharco Pharmaceuticals
• Saudi Pharmaceutical Industries & Medical Appliances Corporation
• TEVA
APPENDIX: LIST OF MAJOR COMPANIES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
• Figure 1-1: Middle East Market Analysis: 2005-201
CHAPTER THREE: PHARMACEUTICAL MARKETS IN ISRAEL
6. • Table 3-1: Israel’s Economic Sectors
• Table 3-2: Israel’s GDP and Healthcare Spending
• Table 3-3: Israel - Midyear Population, by Age and Sex, 2007 and 2012
• Figure 3-1: Israel - Midyear Population, by Age, 2007 and 2012
• Table 3-4: Israel Fertility Rates and Births, Estimated 2000, 2005; Projected
2010, 2015
• Figure 3-2: Israel Fertility Rates and Births, Estimated 2000, 2005; Projected
2010, 2015
• Table 3-5: Israel Life Expectancy at Birth, 2000, 2005; Projections, 2010, 2015
and 2020
• Figure 3-3: Israel Life Expectancy at Birth by Sex, 2000, 2005; Projections 2010,
2015 and 2020
• Table 3-6: Israel Mortality Rates and Numbers, Estimated 2000, 2005; Projected
2010, 2015
• Figure 3-4: Israel Mortality Rates and Numbers, Estimated 2000, 2005; Projected
2010, 2015
• Table 3-7: Tuberculosis Surveillance and Epidemiology, Israel
• Table 3-8: Israel Pharmaceutical Market Analysis, 2005-2007
• Table 3-9: Israel Pharmaceutical Market Analysis: 2008-2012
• Figure 3-5: Israel Pharmaceutical Market Analysis: 2005-2012
• Table 3-10: Estimated Sales of Pharmaceuticals in Israel by Generic Or Brand,
2007
• Figure 3-6: Estimated Sales of Pharmaceuticals in Israel by Generic Or Brand,
2007
CHAPTER FOUR: PHARMACEUTICAL MARKETS IN EGYPT
• Table 4-1: Egypt’s Economic Sectors
• Table 4-2: Egypt’s GDP and Healthcare Spending
• Table 4-3: Egypt - Midyear Population, by Age and Sex, 2007 and 2012
• Figure 4-1: Egypt - Midyear Population, by Age, 2007 and 2012
• Table 4-4: Egypt Fertility Rates and Births, Estimated 2000, 2005; Projected
2010, 2015
• Figure 4-2: Egypt Fertility Rates and Births, Estimated 2000, 2005; Projected
2010, 2015
• Table 4-5: Egypt Life Expectancy at Birth, 2000, 2005; Projections, 2010, 2015
and 2020
• Figure 4-3: Egypt Life Expectancy at Birth by Sex, 2000, 2005; Projections 2010,
2015 and 2020
• Table 4-6: Egypt Mortality Rates and Numbers - Estimated 2000, 2005; Projected
2010, 2015
• Figure 4-4: Egypt Mortality Rates and Numbers: Estimated 2000, 2005; Projected
2010, 2015
• Table 4-7: Tuberculosis Surveillance and Epidemiology, Egypt
• Table 4-8: Egypt Pharmaceutical Market Analysis, 2005-2007
• Table 4-9: Egypt Pharmaceutical Market Analysis: 2008-2012
7. • Figure 4-5: Egypt Pharmaceutical Market Analysis: 2005-2012
• Table 4-10: Estimated Sales of Pharmaceuticals in Egypt by Generic Or Brand,
2007
• Figure 4-6: Estimated Sales of Pharmaceuticals in Egypt by Generic Or Brand,
2007
CHAPTER FIVE: PHARMACEUTICAL MARKETS IN SAUDI ARABIA
• Table 5-1: Saudi Arabia’s Economic Sectors
• Table 5-2: Saudi Arabia’s GDP and Healthcare Spending
• Table 5-3: Saudi Arabia - Midyear Population, by Age and Sex, 2007 and 2012
• Figure 5-1: Saudi Arabia - Midyear Population, by Age, 2007 and 2012
• Table 5-4, Saudi Arabia Fertility Rates and Births - Estimated 2000, 2005;
Projected 2010, 2015
• Figure 5-2: Saudi Arabia Fertility Rates and Births - Estimated 2000, 2005;
Projected 2010, 2015
• Table 5-5: Saudi Arabia Life Expectancy at Birth, 2000, 2005; Projections, 2010,
2015 and 2020
• Figure 5-3: Saudi Arabia Life Expectancy at Birth by Sex, 2000, 2005;
Projections 2010, 2015 and 2020
• Table 5-6: Saudi Arabia Mortality Rates and Numbers, Estimated 2000, 2005;
Projected 2010, 2015
• Figure 5-4: Saudi Arabia Mortality Rates and Numbers - Estimated 2000, 2005;
Projected 2010, 2015
• Table 5-7: Tuberculosis Surveillance and Epidemiology, Saudi Arabia
• Table 5-8: Saudi Arabia Cancer Incidence in Men and Women 2006
• Table 5-9: Saudi Arabia Pharmaceutical Market Analysis, 2005-2007
• Table 5-10: Saudi Arabia Pharmaceutical Market Analysis: 2008-2012
• Figure 5-4: Saudi Arabia Pharmaceutical Market Analysis: 2005-2012
• Table 5-11: Estimated Sales of Pharmaceuticals in Saudi Arabia by Generic Or
Brand, 2007
• Figure 5-5: Estimated Sales of Pharmaceuticals in Saudi Arabia by Generic Or
Brand, 2007
CHAPTER SIX: PHARMACEUTICAL MARKETS IN JORDAN
• Table 6-1: Jordan’s Economic Sectors
• Table 6-2: Jordan’s GDP and Healthcare Spending
• Table 6-3: Jordan - Midyear Population, by Age and Sex, 2007 and 2012
• Figure 6-1: Jordan - Midyear Population, by Age, 2007 and 2012
• Table 6-4: Jordan Fertility Rates and Births - Estimated 2000, 2005; Projected
2010, 2015
• Figure 6-2: Jordan Fertility Rates and Births - Estimated 2000, 2005; Projected
2010, 2015
• Table 6-5: Jordan Life Expectancy at Birth, 2000, 2005; Projections, 2010, 2015
and 2020
8. • Figure 6-3L Jordan Life Expectancy at Birth by Sex, 2000, 2005; Projections
2010, 2015 and 2020
• Table 6-6: Jordan Mortality Rates and Numbers - Estimated 2000, 2005;
Projected 2010, 2015
• Figure 6-4: Jordan Mortality Rates and Numbers - Estimated 2000, 2005;
Projected 2010, 2015
• Table 6-7: Tuberculosis Surveillance and Epidemiology, Jordan
• Table 6-8: Jordan Pharmaceutical Market Analysis, 2005-2007
• Table 6-9: Jordan Pharmaceutical Market Analysis: 2008-2012
• Figure 6-5: Jordan Pharmaceutical Market Analysis: 2005-2012
• Table 6-10: Estimated Sales of Pharmaceuticals in Jordan by Generic Or Brand,
2007
• Figure 6-6: Estimated Sales of Pharmaceuticals in Jordan by Generic Or Brand,
2007
CHAPTER SEVEN: PHARMACEUTICAL MARKETS IN THE UNITED ARAB
EMIRATES
• Table 7-1: United Arab Emirates’ Economic Sectors
• Table 7-2: United Arab Emirates’ GDP and Healthcare Spending
• Table 7-3: UAE - Midyear Population, by Age and Sex, 2007 and 2012
• Figure 7-1: UAE - Midyear Population, by Age, 2007 and 2012
• Table 7-4: UAE Fertility Rates and Births - Estimated 2000, 2005; Projected
2010, 2015
• Figure 7-2: UAE Fertility Rates and Births - Estimated 2000, 2005; Projected
2010, 2015
• Table 7-5: UAE Life Expectancy at Birth, 2000, 2005; Projections, 2010, 2015
and 2020
• Figure 7-3: UAE Life Expectancy at Birth by Sex, 2000, 2005; Projections 2010,
2015 and 2020
• Table 7-6: UAE Mortality Rates and Numbers - Estimated 2000, 2005; Projected
2010, 2015
• Figure 7-4: UAE Mortality Rates and Numbers - Estimated 2000, 2005; Projected
2010, 2015
• Table 7-7: UAE Pharmaceutical Market Analysis, 2005-2007
• Table 7-8: UAE Pharmaceutical Market Analysis: 2008-2012
• Figure 7-5: UAE Pharmaceutical Market Analysis: 2005-2012
• Table 7-9: Estimated Sales of Pharmaceuticals in UAE by Generic Supply, 2007
• Figure 7-6: Estimated Sales of Pharmaceuticals in UAE by Generic Or Brand,
2007
CHAPTER EIGHT: MARKET SUMMARY
• Table 8-1: Pharmaceutical Markets in the Middle East: Market Analysis, 2005-
2007
9. • Table 8-2: Pharmaceutical Markets in the Middle East: Market Analysis: 2008-
2012
• Figure 8-1: Pharmaceutical Markets in the Middle East: Market Analysis: 2005-
2012
• Table 8-3: Middle East Pharmaceutical Markets by Country, 2007
• Figure 8-2: Middle East Pharmaceutical Markets by Country, 2007
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=1646593
US: 800.298.5699
UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004